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Oncogenic Driver Genes and the
Inflammatory Microenvironment
Dictate Liver Tumor Phenotype
Matthias S. Matter,1,2 Jens U. Marquardt,1,3 Jesper B. Andersen,1,4 Cristina Quintavalle,2 Nikolay Korokhov,1 Jim K. Stauffer,5
Kosuke Kaji,1 Thomas Decaens,1 Luca Quagliata,2 Fathi Elloumi,6 Tanya Hoang,2 Alfredo Molinolo,7 Elizabeth A. Conner,1
Achim Weber,8 Mathias Heikenwalder,9,10 Valentina M. Factor,1 and Snorri S. Thorgeirsson1
The majority of hepatocellular carcinoma develops in the background of chronic liver inﬂammation caused by viral
hepatitis and alcoholic or nonalcoholic steatohepatitis. However, the impact of different types of chronic inﬂammatory
microenvironments on the phenotypes of tumors generated by distinct oncogenes is largely unresolved. To address this
issue, we generated murine liver tumors by constitutively active AKT-1 (AKT) and b-catenin (CAT), followed by
induction of chronic liver inﬂammation by 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) and carbon tetrachloride.
Also, the impact of DDC-induced chronic liver inﬂammation was compared between two liver tumor models using a
combination of AKT-CAT or AKT-NRASG12V. Treatment with DDC and carbon tetrachloride signiﬁcantly facilitated
the adenoma-to-carcinoma conversion and accelerated the growth of AKT-CAT tumors. Furthermore, DDC treatment
altered the morphology of AKT-CAT tumors and caused loss of lipid droplets. Transcriptome analysis of AKT-CAT
tumors revealed that cellular growth and proliferation were mainly affected by chronic inﬂammation and caused
up-regulation of Cxcl16, Galectin-3, and Nedd9, among others. Integration with transcriptome proﬁles from human
hepatocellular carcinomas further demonstrated that AKT-CAT tumors generated in the context of chronic liver inﬂam-
mation showed enrichment of poor prognosis gene sets or decrease of good prognosis gene sets. In contrast, DDC had a
more subtle effect on AKT-NRASG12V tumors and primarily enhanced already existent tumor characteristics as supported
by transcriptome analysis. However, it also reduced lipid droplets in AKT-NRASG12V tumors. Conclusion: Our study
suggests that liver tumor phenotype is deﬁned by a combination of driving oncogenes but also the nature of chronic liver
inﬂammation. (HEPATOLOGY 2016; 00:000–000)
Research on hepatocellular carcinoma (HCC)has focused predominantly on the understand-ing of genetic and epigenetic alterations respon-
sible for driving the neoplastic process in the liver. In
recent years, key alterations in HCC tumors have been
identiﬁed and used to predict patient survival and to pro-
vide possible therapeutic targets.(1) However, accumulat-
ing evidence suggests that tumor phenotype is not only
dictated by genetic and epigenetic alterations in the
tumor cells per se but also inﬂuenced by molecular cross-
talk between tumor cells and the surrounding microen-
vironment.(2) This concept is particularly relevant for
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liver cancer, where the majority of HCCs (up to 90%)
develop in the background of chronic liver inﬂammation
caused by hepatitis B or C virus, alcoholic steatohe-
patitis, or nonalcoholic steatohepatitis.(3) Although the
recognition that the hepatic microenvironment contrib-
utes to tumor phenotype is generally accepted, the extent
to which it affects HCC phenotype, including biology,
remains unresolved. A direct comparison between HCC
developing in noncirrhotic liver and cirrhotic liver could
give some insight into the role of chronic inﬂammation.
However, the results are difﬁcult to interpret because
compared tumors would need to have the same molecu-
lar features, such as identical mutations, which is an
almost impossible requirement to meet in a clinical
setting.(4)
Therefore, we genetically engineered liver tumors
using different combinations of oncogenes with two
inﬂammation-promoting regiments. This approach
allowed us to address the impact of (1) the different
microenvironment on the same tumor type and (2)
the same microenvironment on different tumor
types. To initiate liver tumors, we employed
oncogenes known to be frequently activated in HCC:
b-catenin (CAT), NRASG12V, and AKT-1
(AKT).(1) Chronic liver inﬂammation was induced by
feeding mice 3,5-diethoxycarbonyl-1,4-dihydrocolli-
dine (DDC), a nongenotoxic hepatotoxin causing
portal inﬂammation and ﬁbrosis.(5) As a second
inﬂammatory model, we used chronic administration
of carbon tetrachloride (CCl4), resulting in centrilob-
ular liver damage with accompanying inﬂammation
and ﬁbrosis.(6)
Our results provide evidence that chronic inﬂamma-
tion driven by the DDC diet or exposure to CCl4 had
a profound impact on liver tumor phenotype. Both
inﬂammation-promoting regimens increased tumor
growth, accelerated malignant conversion, and caused
inﬂammation-speciﬁc changes in the tumor trans-
criptome of AKT-CAT tumors. DDC-mediated
inﬂammation also inﬂuenced the biology of AKT-
NRASG12V-driven hepatocarcinogenesis, albeit to a
lesser degree compared to AKT-CAT tumors. We
conclude that the outcome of liver cancer development
is dependent on the cooperation between initiating
oncogenes and the nature of inﬂammation.
Materials and Methods
HYDRODYNAMIC INJECTION,
VECTOR CONSTRUCTS
For tumor generation, oncogenic plasmids and
sleeping beauty transposase (ratio of 10:1) were diluted
in 2 mL saline (0.9% NaCl) and injected into the tail
vein of FVB/n female mice 6-8 weeks old (National
Cancer Institute, Frederick, MD) in 5-7 seconds.(7)
For AKT-CAT tumors, plasmids encoding for acti-
vated AKT (myristoylated AKT) and CAT (truncated
D90N-CAT) were used.(8) For AKT-NRASG12V
tumors, AKT1 and N-RasG12V plasmids were used.(7)
For chronic liver inﬂammation, mice received a diet
containing 0.1% DDC (Bio-Serv, Flemington, NJ) or
were treated intraperitoneally twice a week with CCl4
(Sigma) diluted 1:10 in mineral oil (Sigma) at 5 lL/g
body weight. Mice were kept in accordance with the
animal regulations at the National Cancer Institute/
National Institutes of Health (Bethesda, MD).
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STATISTICS
Data were analyzed using the Student t test. P values
<0.05 were considered signiﬁcant.
MICROARRAY DATA ANALYSIS
Microarray analysis was performed from four mice
per tumoral group and three mice per nontumoral and
control group. RNA was isolated from fresh frozen tis-
sue using the RNAeasy kit from Qiagen (Valencia,
CA) and pooled from three to four histologically
conﬁrmed hepatocellular tumors per mouse and one to
two locations of nontumoral tissue and control liver
tissue of age-matched and sex-matched mice on
normal chow. RNA was hybridized on Sentrix Mouse
Ref-8v2.0 expression BeadChips (Illumina, San Diego,
CA) and scanned on an iSCAN (Illumina). Data pre-
processing and quantile normalization with background
subtraction were performed with GenomeStudio2010
(Illumina). A signal intensity with a detection P > 0.05
was treated as a missing value, and only genes repre-
sented in at least 50% of all samples were included.
Data analysis was performed with Qlucore (Lund, Swe-
den). Functional analyses were performed by gene set
enrichment analysis (GSEA) and Ingenuity Pathway
Analysis (IPA8.7; Ingenuity Systems, Redwood City
CA). All microarray data were submitted to Gene
Expression Omnibus (GSE77503). If not stated other-
wise, signiﬁcantly different expressed genes between
two groups were identiﬁed using a P value of 0.001 and
a fold-change difference of 1.5.
See the Supporting Information for additional
information.
Results
DDC AND CCL4 EXPOSURE
CAUSED CHRONIC LIVER
INFLAMMATION
Liver tumors were engineered by myristoylated
and therefore activated AKT and activated truncated
CAT, introduced into mouse hepatocytes by hydrody-
namic tail vein injection.(8) Three days after injection,
mice were exposed to a DDC diet (AKT-CAT1DDC
group) or kept on standard chow (AKT-CAT group).
The DDC diet was tolerated well by all mice and caused
typical liver pathology, which included progressive
protoporphyria with pigment deposition, formation of
Mallory-Denk bodies, and hepatomegaly (data not
shown).(5) In addition, DDC affected the portal area,
where it caused a pronounced ductular reaction of biliary
cells and a chronic inﬂammation containing CD31
T cells and Ly6.G1 neutrophils (Fig. 1). Mice under
continuous DDC treatment developed moderate ﬁbro-
sis in the portal tract with few portal-to-portal septa,
which started to form after 4-6 weeks of diet onset and
gave a nodular appearance (Fig. 1, sirius red stain).
Alternatively, chronic inﬂammation was induced by
CCl4 administration. Three days after hydrodynamic
injection of AKT-CAT plasmids, mice received the ﬁrst
intraperitoneal injection of CCl4, which was continued
thereafter twice a week (AKT-CAT1CCl4 group).
Chronic exposure to CCl4 caused centrilobular and por-
tal inﬂammation, which consisted mainly of Ly6.G1
neutrophil granulocytes and CD31 T lymphocytes
(Fig. 1). Continuous CCl4 administration provoked
mild to moderate ﬁbrosis around central veins with few
central-to-central septa (Fig. 1, sirius red stain) starting
after 4-6 weeks of treatment onset. No tumor nodules
were found 4-6 weeks after hydrodynamic injection,
and typical DDC or CCl4 liver pathology was inde-
pendent from stable AKT-CAT expression.
CHRONIC INFLAMMATION
INDUCED BY DDC AND CCL4
ENHANCED GROWTH OF
AKT-CAT TUMORS
On average, 17.9 6 3.4 weeks after hydrodynamic
injection, AKT-CAT mice developed ascites due to
excessive liver tumor growth or showed palpable liver
nodules and had to be sacriﬁced. Macroscopic analysis
revealed numerous liver tumor nodules in AKT-CAT
mice (n 5 8) (Fig. 2A). DDC treatment considerably
accelerated tumor growth, and AKT-CAT1DDC
mice (n 5 7) had to be sacriﬁced at 11.0 6 2.8 weeks
after hydrodynamic injection (Fig. 2A). By this time,
AKT-CAT1DDC tumors reached up to 5 mm in
diameter, whereas the maximal diameter of the age-
matched AKT-CAT tumors was <1 mm (Fig. 2A).
Similarly, growth of AKT-CAT tumors was enhanced
in the inﬂammatory environment generated by CCl4.
AKT-CAT1CCl4 mice had to be sacriﬁced 13.6 6
0.8 weeks (n 5 4) after hydrodynamic injection,
when liver tumor nodules were up to 4 mm in diameter
(Fig. 2A).
Interestingly, in AKT-CAT1DDC mice, there
were fewer tumors, but they were larger compared to
those in AKT-CAT and AKT-CAT1CCl4 mice
(Fig. 2B). This suggests that DDC interfered with
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tumor initiation while promoting growth of the estab-
lished tumors. Of note, control mice maintained on
the DDC diet (n 5 7) for 26 weeks did not develop
any neoplastic lesions. Similarly, mice treated continu-
ously with CCl4 (n 5 8) for 20 weeks did not generate
tumors. In addition, no tumor development was
detected after injection of AKT or CAT alone
to either untreated mice (n 5 6 for each oncogene,
26 weeks of observation) or DDC-treated mice (n 5 3
mice/group, 12 weeks of observation).
Immunohistochemistry for CAT showed strong
nuclear staining with a similar intensity in all three
types of AKT-CAT tumors (Fig. 2C). Likewise, the
staining intensity for the second oncogene, activated
AKT (phosphorylated AKT473), was also comparable
in all AKT-CAT tumors, although it was considerably
weaker (Fig. 2C). This conﬁrmed a similar expression
of both oncogenes in all three different AKT-CAT
tumor models. To exclude that DDC diet or CCl4
exposure changed the distribution or type of in vivo
transfected liver cells, we performed hydrodyna-
mic injection with a green ﬂuorescent protein (GFP)-
positive plasmid, followed by treatment with DDC or
CCl4 for 7 and 12 days. Consistently, only hepatocytes
showed GFP signals, regardless of treatment (Support-
ing Fig. S1). GFP-expressing hepatocytes were pri-
marily located in the central and pericentral areas
(zones 1 and 2) of the hepatic lobule. Cholangiocytes
and progenitor cells did not display GFP positivity
and, therefore, as shown before, were not transfected
after hydrodynamic injection.(9) There were no quanti-
tative differences in GFP expression between untreated
and DDC-treated mice on days 7 and 12 after hydro-
dynamic injection. Mice treated with CCl4 showed a
slight reduction in the number of GFP-positive hepa-
tocytes, most likely due to the pericentral necrosis
caused by the ﬁrst CCl4 injection.
(6) Furthermore, we
compared the integrated AKT plasmid copy number
in AKT-CAT, AKT-CAT1DDC, and AKT-
CAT1CCl4 tumors. Quantitative polymerase chain
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FIG. 1. Chronic liver inﬂammation caused
by DDC and CCl4 treatment. Three days
after hydrodynamic injection of AKT-CAT
plasmids, mice remained on standard chow
(AKT-CAT), were subjected to a DDC
diet (AKT-CAT1DDC), or were treated
with intraperitoneal CCl4 administration
(AKT-CAT1CCl4). Hematoxylin and
eosin, immunohistochemistry for CD3 and
Ly6.G, and sirius red after at least 6 weeks
of DDC or CCl4 treatment. For all pic-
tures one representative image is shown
from each group (four to nine mice per
group). Bar 5 100 lm. Abbreviations: C,
central vein; H&E, hematoxylin and eosin;
P, portal tract.
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reaction showed that integrated AKT plasmid copy
number was very similar in all three tumor groups
(Fig. 2D). Further, liver cell lines (SNU-449 and
PLC/PRF/5) treated with DDC did not show changes
in proliferation rate (Supporting Fig. S2). Altogether,
these results indicate that the inﬂammatory microen-
vironment, rather than increased plasmid integration,
change in cell type transfected, or direct effect of DDC
on hepatocytes, was responsible for the promotion of
tumor growth.
CHANGE OF TUMOR
PHENOTYPE IN THE
BACKGROUND OF CHRONIC
LIVER INFLAMMATION
We next performed a more detailed histopathologi-
cal assessment of tumor lesions according to a recent
consensus report on murine liver tumor classiﬁcation,
which differs from human liver tumor classiﬁcation.(10)
Three types of AKT-CAT driven liver tumors were
recognized: hepatocellular adenoma (HCA), mixed
HCA-HCC, and hepatoblastoma. A mixed HCA-
HCC was diagnosed if at least 5% of the HCA was
composed of an HCC. In contrast to human liver
tumors, a focus of an HCC within an HCA is a
common feature in murine liver tumors, thought to
reﬂect the conversion of an HCA to a more malignant
HCC phenotype.(10,11) The predominant tumor type
in all three groups was either HCA or mixed HCA-
HCC (Fig. 3A). Pure HCC was not detected, and no
metastasis was found in any of the tumor groups.
Chronic inﬂammation increased the frequency of liver
tumors with a mixed phenotype from 19% in untreated
mice to 46% and 27% in DDC-treated and CCl4-
treated mice, respectively (Fig. 3A). Chronic inﬂam-
mation also caused a marked expansion of the HCC
component within the mixed HCA-HCCs. In AKT-
CAT mice, the percentage of mixed HCA-HCC
ranged between 5% and 25%, whereas it was 5%-50%
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FIG. 2. AKT-CAT tumors generated in the background of chronic liver inﬂammation. (A) Representative macroscopic liver pictures
containing AKT-CAT, AKT-CAT1DDC, or AKT-CAT1CCl4 tumors in weeks after hydrodynamic injection. Bar 5 1 cm (four
to nine mice per group). Arrow indicates tumor nodule. (B) Histogram with number of liver tumor nodules with a diameter >2 mm
and visible from the outside at the time of sacriﬁce. Mean and standard error of the mean from four to nine mice/group. (C) AKT-
CAT, AKT-CAT1DDC, and AKT-CAT1CCl4 tumors analyzed for b-catenin and p-AKT by immunohistochemistry. Bar 5
50lm. (D) Total copy number of pT3 plasmid/DNA in AKT-CAT, AKT-CAT1DDC, and AKT-CAT1CCl4 tumors. Mean and
standard error of the mean of six samples per group. For all pictures, one representative image is shown from each group.
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and 5%-60% in AKT-CAT1DDC and AKT-
CAT1CCl4 mice, respectively. Thus, chronic inﬂam-
mation promoted the progression of murine HCA into
HCC. In addition, a minority of tumors was classiﬁed
as hepatoblastoma. Hepatoblastoma were found only
in AKT-CAT and AKT-CAT1DDC mice without
any difference in morphology. Therefore, for adequate
comparison between all three AKT-CAT tumor
groups, further analyses were performed only on hepa-
tocellular tumors (HCA and mixed HCA-HCC).
In accordance with earlier observations,(8) most
AKT-CAT tumors (84.1 6 9.7%) were steatotic and
contained lipid droplets as conﬁrmed by oil-red O
staining (Fig. 3B). Tumors were deﬁned as steatotic if
>50% of the tumor cells showed lipid droplets. In con-
trast, none of the AKT-CAT1DDC tumors were
steatotic, but 69.8 6 10.3% of the AKT-CAT1CCl4
tumors were steatotic (Fig. 3B, hematoxylin and eosin
and oil red O). In contrast, the number of tumor inﬁl-
trating CD31 T cells was similar in all AKT-CAT
tumors, and only a few single intratumoral Ly6.G1
neutrophils could be found (Supporting Fig. S3).
CHANGE OF TUMOR
TRANSCRIPTOME IN THE
BACKGROUND OF CHRONIC
LIVER INFLAMMATION
We performed transcriptome analysis of the AKT-
CAT tumors developed with an inﬂammatory micro-
environment modiﬁed by either the DDC diet or
CCl4 exposure. All tumors selected for microarray
analysis had a similar size (3.0-3.4 mm in diameter)
and were examined by histology to ensure that only
hepatocellular tumors were included. Analysis was per-
formed with four mice per experimental group, and
RNA was pooled after isolation from three to four
tumor nodules from each mouse. Unsupervised hier-
archical clustering (average linkage) of all detected
genes (n 5 9037) clearly subdivided tumoral and non-
tumoral tissue into distinct clusters according to the
experimental groups (Fig. 4A; Supporting Fig. S4).
This conﬁrmed that background inﬂammation
induced drastic changes of the tumor transcriptome.
Next, we identiﬁed genes differentially expressed in
each tumor group in comparison to normal untreated
liver. In total, 336 genes were differently expressed in
AKT-CAT tumors, 630 genes in AKT-CAT1DDC
tumors, and 572 genes in AKT-CAT1CCl4 tumors
(Supporting Tables S1-S3). To characterize the path-
ways most affected by DDC and CCl4 treatment, we
used Ingenuity Pathway Analysis (IPA). In each group
we identiﬁed the top ﬁve pathways associated with dis-
ease and function and searched for the differences
between the tumor groups. “Cell death and survival”
and “cancer” were shared among all AKT-CAT
tumors (Table 1); however, P values were higher in
DDC-treated and CCl4-treated tumors. “Cellular
growth and proliferation” exempliﬁed the AKT-
CAT1DDC and AKT-CAT1CCl4 tumors, while in
AKT-CAT tumors this function was ranked only sev-
enteenth. Accordingly, cell proliferation as measured
by Ki-67 conﬁrmed that tumor growth rate was con-
siderably higher in AKT-CAT1DDC and AKT-
CAT1CCl4 tumors compared to AKT-CAT tumors
(Fig. 4B). The remaining most affected pathways were
unique for each group (see Table 1). Thus, the back-
ground inﬂammation had a strong impact on pathway
activation in each AKT-CAT tumor group.
Next, we analyzed the “cellular growth and pro-
liferation” network, which contained 205 genes for
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FIG. 3. Histological analysis of AKT-CAT tumors generated in
the background of chronic liver inﬂammation. (A) Distribution
of HCA and mixed HCA-HCC (with percentage) within total
number of hepatocellular tumors. (B) Hematoxylin and eosin and
oil red O of AKT-CAT, AKT-CAT1DDC, and AKT-
CAT1CCl4 tumors. Bar 5 50 lm. One representative picture
of four to nine mice per group. Abbreviations: HE, hematoxylin
and eosin; NT, nontumoral tissue; T, tumoral tissue.
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MATTER ET AL. HEPATOLOGY, Month 2016
6
AKT-CAT1DDC tumors and 169 genes for AKT-
CAT1CCl4 tumors (Supporting Tables S4 and S5).
Comparison between these two gene sets identiﬁed
Col4a2, Cxcl16, Elf3, Galectin-3, Lxn, Mvp, and
Nedd9, which were shared by AKT-CAT1DDC and
AKT-CAT1CCl4 tumors and which showed further-
more a signiﬁcant deregulation from AKT-CAT
tumors (P < 0.01, fold change >1.5). As Cxcl16,
Galectin-3, and Nedd9 have been associated with
worse prognosis in HCC patients,(12-14) we tested their
expression by quantitative polymerase chain reaction
(Supporting Fig. S5). Indeed, their expression was
highest in AKT-CAT1DDC and AKT-CAT1CCl4
tumors.
AKT-CAT1DDC tumors also showed an increase
in pathways connected to vascular disease, which
included atherosclerosis and arteriosclerosis. AKT-
CAT1CCl4 tumors showed a signiﬁcant change in
cardiovascular system development and function,
which included proliferation and migration of endo-
thelial cells as well as neovascularization. Yet, micro-
vessel density remained similar in all AKT-CAT
tumor groups (Supporting Fig. S6).
Histologically, one of the most striking characteris-
tics of DDC-treated tumors was loss of lipid droplets.
IPA showed that lipid metabolism was more signiﬁ-
cantly changed in AKT-CAT1DDC tumors (P 5
5.62E08-2.46E-3) than in AKT-CAT tumors (P 5
1.71E03-1.33E02) and AKT-CAT1CCl4 tumors
(P 5 5.53E04-9.67E03). Detailed analysis showed
that synthesis, ﬂux, efﬂux, and uptake of lipids, as well
as uptake and metabolism of fatty acid, were affected
in AKT-CAT1DDC tumors and that the majority of
these functions showed a reduced activation score. To
corroborate the involvement in lipid metabolism fur-
ther, we determined the content of cholesteryl esters
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FIG. 4. Transcriptome of AKT-CAT tumors generated in the
background of chronic liver inﬂammation. (A) Unsupervised hier-
archical clustering of gene expression proﬁles from AKT-CAT,
AKT-CAT1DDC, and AKT-CAT1CCl4 tumors. (B) Percent-
age of proliferating Ki-67-positive hepatocytes within total hepa-
tocytes, measured by immunohistochemistry. Mean and standard
error of the mean from seven to eight tumors per group. (C) Cho-
lesteryl ester concentration in AKT-CAT, AKT-CAT1DDC,
and AKT-CAT1CCl4 tumors. Mean and standard error of the
mean of four tumor samples per group. (D) GSEA of AKT-CAT
and AKT-CAT1DDC tumors using a gene set with good prog-
nosis (left) and of AKT-CAT and AKT-CAT1CCl4 tumors
using a gene set with bad prognosis (right). (E,F) GSEA of non-
tumoral tissue of AKT-CAT and AKT-CAT1DDC mice (E) or
mice treated with DDC only (F) using gene sets with low and
high risks of late recurrence. Abbreviations: FDR, false discovery
rate; NES, normalized enrichment score.
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and triglycerides, which are both stored in lipid
droplets.(15) Cholesteryl ester concentration was sig-
niﬁcantly reduced in AKT-CAT1DDC tumors in
comparison to AKT-CAT tumors, whereas AKT-
CAT1CCl4 tumors had an intermediate concentra-
tion (Fig. 4C). Triglycerides were only slightly
reduced in AKT-CAT1DDC tumors (Supporting
Fig. S7). Accordingly, proteins which are involved in
fatty acid and cholesterol metabolism(16)—fatty acid
synthase, phospho-adenosine triphosphate-citrate
lyase, mammalian long chain acyl-coenzyme A syn-
thetase, cytoplasmic acetyl-coenzyme A synthetase,
and phospho-S6-ribosomal protein—showed reduced
expression in AKT-CAT1DDC and AKT-CAT1
CCl4 tumors (Supporting Fig. S7).
GSEA OF TUMORAL AND
NONTUMORAL TISSUE
Next, we performed cross-species comparison and
GSEA to relate our murine data to human data.(17)
We used our previously published human HCC gene
sets, which deﬁne HCC patients with good and bad
prognosis.(18) Consistent with a more aggressive phe-
notype of tumors grown in the inﬂammatory environ-
ment, AKT-CAT1DDC tumors were characterized
by a signiﬁcant decrease of good prognosis genes
(Fig. 4D) and AKT-CAT1CCl4 tumors showed
an enrichment of poor prognosis genes (Fig. 4D).
Thus, the biology of AKT-CAT1DDC and AKT-
CAT1CCl4 tumors showed similarities with human
HCCs.
Given the importance of the nontumoral liver tissue
in HCC prognosis, we performed transcriptome analy-
sis of the nontumoral murine liver tissue by microarray
and executed GSEA with gene sets from HCC
patients with low or high risk of HCC recurrence.(19)
Nontumoral liver tissue from AKT-CAT1DDC mice
showed enrichment of genes with high risk of late
recurrence and, vice versa, the genes with low risk of
late recurrence were enriched in AKT-CAT nontu-
moral liver tissue (Fig. 4E). Therefore, the worse out-
come of tumor-bearing mice under DDC treatment
was deducible not only from tumoral transcriptome
but also from the nontumoral transcriptome, similar to
HCC patients. Interestingly, liver tissue from tumor-
free mice treated only with DDC revealed an even fur-
ther enrichment of genes related to worse prognosis
(Fig. 4F). Therefore, AKT-CAT tumors provoked
changes in the nontumoral liver tissue, which
improved prognosis. In contrast, there was no predic-
tive value of the nontumoral liver tissue from CCl4-
treated mice using these gene sets at a false discovery
rate of <0.25.
IMPACT OF DDC TREATMENT
ON AKT-NRASG12V-DRIVEN
HEPATOCARCINOGENESIS
Furthermore, we asked whether a tumor driven by a
different combination of oncogenes would be similarly
affected by chronic liver inﬂammation. To address this
issue, we generated liver tumors by hydrodynamic injec-
tion of AKT and mutated NRASG12V and placed the
mice on either a DDC diet (AKT-NRASG12V1DDC)
or normal chow (AKT-NRASG12V). AKT-NRASG12V
tumors were more aggressive than AKT-CAT tumors,
and AKT-NRASG12V mice had to be sacriﬁced
10 weeks after hydrodynamic injection (versus 17.9 weeks
for AKT-CAT model). AKT-NRASG12V1DDC mice
had to be sacriﬁced slightly earlier, at 8.4 weeks after
hydrodynamic injection, mainly due to ascites formation.
Most of the liver tissue was occupied by tumor nodules
in both groups at the time of sacriﬁce (Fig. 5A). DDC
treatment did not signiﬁcantly inﬂuence either the num-
ber of AKT-NRASG12V tumor nodules (Fig. 5B) or the
proliferation rate as measured by immunohistochemistry
TABLE 1. Most Significant Diseases and Function
Affected in AKT-CAT, AKT-CAT1DDC, and
AKT-CAT1CCl4 Tumors
Tumor group P
Shared by all tumor groups
AKT-CAT
Cell death and survival 6.68E-07-1.33E-02
Cancer 2.32E-06-1.34E-02
AKT-CAT1DDC
Cell death and survival 5.2E-14-2.29E-03
Cancer 6.03E-11-2.46E-03
AKT-CAT1CCl4
Cell death and survival 1.82E-09-1.04E-02
Cancer 2.33E-06-1.05E-02
Shared by AKT-CAT1DDC and AKT-CAT1CCl4
AKT-CAT1DDC
Cellular growth and proliferation 1.75E-13-2.23E-03
AKT-CAT1CCl4
Cellular growth and proliferation 5.12E-10-1.06E-02
Unique in each tumor group
AKT-CAT
Cell signaling 6.7E-07-3.53E-03
Tumor morphology 2.32E-06-1.33E-02
Organismal injury and abnormalities 1.28E-05-1.33E-02
AKT-CAT1DDC
Cardiovascular disease 2.01E-10-2.29E-03
Development disorder 1.17E-09-4.97E-04
AKT-CAT1CCl4
Cardiovascular system development and function 6.19E-08-1.02E-02
Organismal development 6.19E-08-1.02E-02
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for Ki-67 (Fig. 5C). Oncogene expression was similar in
both tumor groups, as measured by the expression of
extracellular signal-regulated kinase, a downstream target
of RAS activation and phosphorylated AKT (Fig. 5D).
Histologically, the majority of AKT-NRASG12V tumors
were classiﬁed as HCC.(7) As shown,(7) we also found
cholangiocarcinomas (CCCs) or mixed HCC-CCC
(Supporting Fig. S8). The DDC diet did not change the
relative proportion of HCC, CCC, and mixed HCC-
CCC, which varied 80%-82%, 10%-12%, and 6%-10%
in the two groups (Fig. 5E). However, analogous to
AKT-CAT tumors, DDC treatment caused a reduction
in lipid accumulation in (Fig. 5F), and average percentage
of steatotic HCCs decreased from 56.1% in AKT-
NRASG12V HCCs to 13.5% in AKT-NRASG12V1
DDC tumors (data not shown). No metastasis was
found in any of the tumor groups.
Transcriptome of histologically conﬁrmed HCCs
with similar size from AKT-NRASG12V and AKT-
NRASG12V1DDC mice was analyzed. Unsupervised
hierarchical clustering of all detected genes (n 5 9037)
clearly separated tumors into two clusters determined by
DDC treatment (Supporting Fig. S9). In total, 1629
genes were differently expressed in AKT-NRASG12V
tumors and 1913 genes in AKT-NRASG12V1DDC
tumors in comparison to normal untreated liver tissue.
IPA of the differentially expressed genes showed that
the pathways affected were mostly shared in both exper-
imental groups (Table 2). However, P values were
always higher in AKT-NRASG12V1DDC tumors,
indicating that DDC mainly enhanced the differences
of the changed pathways. Yet, cross-species comparison
and GSEA with our published human gene sets(18) fur-
ther demonstrated an enrichment of poor prognosis
gene sets in AKT-NRASG12V1DDC tumors and of
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FIG. 5. (A) Macroscopic liver pictures with AKT-NRASG12V or
AKT-NRASG12V1DDC tumors. Bar 5 1 cm. (B) Number of
liver tumor nodules >2 mm in diameter visible from outside in
AKT-NRASG12V or AKT-NRASG12V1DDC mice at the time of
sacriﬁce. Mean and standard error of the mean from three to four
mice per group. (C) Percentage of Ki-67-positive hepatocytes
within total hepatocytes, measured by immunohistochemistry. Mean
and standard error of the mean of six to nine tumor samples/group.
(D) Immunohistochemistry for phosphorylated AKT and phospho-
rylated extracellular signal-regulated kinase in AKT-NRASG12V and
AKT-NRASG12V1DDC tumors. (E) Distribution of HCC,
CCC, and mixed HCC-CCC in AKT-NRASG12V and AKT-
NRASG12V1DDC tumors from three to four mice per group. (F)
Hematoxylin and eosin and oil red O staining of AKT-NRASG12V
and AKT-NRASG12V1DDC tumors. Abbreviations: H&E,
hematoxylin and eosin; n.s., nonsigniﬁcant; NT, nontumoral tissue;
pERK, phosphorylated extracellular signal-regulated kinase; T,
tumoral tissue.
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good prognosis gene sets in AKT-NRASG12V tumors
(Supporting Fig. S9), further supporting that biology of
AKT-NRASG12V1DDC tumors reﬂected human
HCC.
Finally, we wanted to compare effects exerted by DDC
on AKT-CAT tumors with the DDC effects on AKT-
NRASG12V tumors. A bioequivalence test(20) of similar-
ities at a fold change >1.5 and P < 0.05 revealed that
90.1% of the genes were similarly expressed between
AKT-CAT and AKT-CAT1DDC tumors and 94.9%
between AKT-NRAS and AKT-NRASG12V1DDC
tumors. Therefore, DDC had a more pronounced effect
on AKT-CAT tumors than on AKT-NRASG12V
tumors. For direct comparison of DDC effects we nor-
malized AKT-CAT1DDC to AKT-CAT and AKT-
NRASG12V1DDC to AKT-NRASG12V and compared
the two groups. We identiﬁed a total of 393 genes signiﬁ-
cantly changed between normalized AKT-CAT1DDC
and AKT-NRASG12V1DDC data sets. IPA showed
that the most signiﬁcantly changed pathway by DDC in
AKT-CAT tumors in comparison to AKT-NRASG12V
tumors was “cellular growth and proliferation” (Support-
ing Table S6), followed by “cellular assembly and organ-
ization,” “cardiovascular system development and
function,” “organismal survival,” and “cancer.” Therefore,
DDC had a different effect on AKT-CAT tumors than
on AKT-NRASG12V tumors.
Discussion
Several studies have revealed the importance of the
inﬂammatory liver microenvironment in HCC devel-
opment. For example, it has been shown that progno-
sis of HCC patients can be predicted by the gene
signature of nontumoral liver tissue.(19,21) Further-
more, HCC patients with an increase of T helper 2
cytokines in relation to T helper 1 cytokines in nontu-
moral liver tissue revealed increased venous metastasis
and poor prognosis.(22) However, many of the mecha-
nisms linking inﬂammation to tumor development
remain unclear, and little is known as to what extent
chronic liver inﬂammation contributes to HCC phe-
notype. In this study, we developed an experimental
mouse model, in which murine liver tumors were
driven by speciﬁc oncogenes and developed in different
inﬂammatory conditions. Chronic inﬂammation pro-
moted tumor growth and aggressiveness but had a
stronger effect on AKT-CAT tumors than on AKT-
NRASG12V tumors. Therefore, liver tumor phenotype
is dependent on the interplay between oncogenic driver
genes and the microenvironment.
Our study goes along with earlier murine studies,
which also described a tumor promoting effect by
DDC or CCl4.
(23,24) We noted that both DDC and
CCl4 affected especially “cell growth and proliferation”
in AKT-CAT tumors and that Galectin-3, Nedd9,
and Cxcl16 were among several genes speciﬁcally up-
regulated. These three genes have been associated
additionally with worse prognosis in human HCC.(12-14)
Galectin-3 has been shown to promote tumor progres-
sion and metastasis formation in HCC.(25) Interestingly,
Galectin-3 has also been reported to be up-regulated in
injured liver(26) and may therefore link chronic liver
damage and tumor development. Similarly, Cxcl16 and
its receptor CXCR16, as well as Nedd9, have been
shown to be involved in HCC progression and metasta-
sis formation.(27,28) AKT-CAT1DDC and AKT-
CAT1CCl4 tumors also showed a higher proportion of
HCCs, and GSEA conﬁrmed that changes in tumoral
and nontumoral tissue reﬂected human HCC biology.
Interestingly, DDC treatment induced loss of lipid
droplets with a reduction in cholesteryl content in AKT-
CAT tumors. Accordingly, several genes involved in
fatty acid and cholesterol metabolism were reduced
in AKT-CAT1DDC and AKT-CAT1CCl4 tumors
in comparison to AKT-CAT tumors.
Several effects appreciated in AKT-CAT tumors
under DDC treatment, such as lipid loss and a
decreased expression of genes associated with good
survival by GSEA, were also observed in AKT-
NRASG12V1DDC tumors. However, in line with the
bioequivalence test, the impact of DDC treatment on
AKT-NRASG12V tumors was less pronounced and
was primarily an enhancement of changes already pro-
cured by AKT-NRASG12V. For example, the effect on
TABLE 2. Most Significant Diseases and Function Affected
in AKT-NRASG12V and AKT-NRASG12V1DDC Tumors
Tumor group P
Shared pathways
AKT-NRASG12V
Cellular growth and proliferation 4.73E-22-4.11E-04
Cell death and survival 1.51E-16-6.42E04
Cardiovascular system development and function 2.17E-15-6.42E-04
Cancer 3.19E-14-6.16E04
AKT-NRASG12V1DDC
Cellular growth and proliferation 4.17E-30-4.02E-05
Cell death and survival 8.54E-29-5.3E-05
Cancer 4.66E-21-5.14E-05
Cardiovascular system development and function 1.44E-18-4.21E-05
Unique pathways
AKT-NRASG12V
Organismal survival 5.95E-17-1.83E-04
AKT-NRASG12V1DDC
Organismal injury and abnormalities 4.66E-21-5.2E-05
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pathways involved in cell growth and proliferation was
negligible. Direct comparison between AKT-CAT
and AKT-NRASG12V tumors also revealed that DDC
had a different effect on AKT-CAT tumors compared
to AKT-NRASG12V tumors. As expected, the effect
on “cell growth and proliferation” was the most signiﬁ-
cant difference.
The differences in the response to inﬂammatory
stimuli between AKT-CAT and AKT-NRASG12V
tumors may be explained in two ways. First, untreated
AKT-NRASG12V tumors were more proliferative,
grew signiﬁcantly faster, and had a more aggressive
phenotype than untreated AKT-CAT tumors. This
suggests that fast-growing malignant tumors are less
susceptible to the inﬂammatory microenvironment and
more likely to survive under adverse conditions. Sec-
ond, there may be oncogene-speciﬁc differences in the
response to cytokines or chemokines produced by the
tumor microenvironment. Thus, it has been recently
shown that CAT has an intrinsic proinﬂammatory
transcriptional program.(29) Therefore, AKT-CAT
tumors may be more susceptible to inﬂammatory stim-
uli than AKT-NRASG12V tumors.
Although we demonstrated that chronic inﬂamma-
tion plays an important role in tumor phenotype, our
results do not allow differentiation of whether the phe-
notype is deﬁned by the best-ﬁt tumor cells capable of
surviving in the background inﬂammation or by the
plasticity of tumor cells with transformation into a
more aggressive phenotype under the pressure of
chronic inﬂammation. DDC-treated mice showed a
reduction in the number of AKT-CAT tumor nod-
ules, suggesting that only selective tumor cells had the
ability to survive in the background of chronic inﬂam-
mation driven by DDC and that some tumor cells may
have been eliminated by chronic inﬂammation. This
notion is supported by the fact that chronic inﬂamma-
tion can either promote or inhibit tumor growth.(2) In
contrast, the number of AKT-CAT tumors was simi-
lar in untreated and CCl4-treated mice, indicating that
inﬂammation caused by CCl4 promoted a transforma-
tion into a more aggressive phenotype. Therefore, the
appreciated change in phenotype of AKT-CAT
tumors was most likely a combination of both selection
and transformation of tumor cells.(30)
In conclusion, our study provides evidence that the
inﬂammatory milieu changes the behavior and pheno-
type of HCC in a manner dependent on the driving
oncogenes. Furthermore, tumors with the same muta-
tions and driving oncogenes may have substantially
different transcriptome depending on the type of
inﬂammation. As a consequence, response to systemic
cancer treatment may also depend on the tumor
microenvironment.
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